Biotech Values

[DewDiligence]

NTGN clinical milestones:

https://globenewswire.com/news-release/2018/08/06/1547708/0/en/Neon-Therapeutics-Reports-Second-Quarter-2018-Financial-Results-and-Recent-Business-Highlights.html

NEO-PV-01
• NT-001: Phase 1b Clinical Trial of NEO-PV-01 in the Metastatic Setting
. Updated data expected in October 2018 at ESMO
. 52-week data expected in the first half of 2019
• NT-002: Phase 1b Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer
. 52-week data expected in the second half of 2019
• NT-003: Phase 1b Clinical Trial of NEO-PV-01 in Metastatic Melanoma Combinations
. Trial initiation expected in the second half of 2018
• NT-004: Phase 1b Clinical Trial of NEO-PV-01 in Earlier Disease Setting
. Planning ongoing

NEO-PTC-01
• Phase 1 Clinical Trial in Solid Tumor Setting: Neon intends to submit a European Clinical Trial Application (CTA) for NEO-PTC-01, a personal neoantigen T-cell therapy, in the first half of 2019.

NEO-SV-01
• Phase 1 Clinical Trial in Subset of ER+ Breast Cancer: Following the completion of target validation and preclinical product development work, Neon expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the first half of 2019.

6/30/18 cash=$138.6M. No CC.